BioCentury | Aug 26, 2020

Partnerships paved the way to a Tokyo IPO for Modalis

Modalis paved its way to a public listing on the Tokyo Stock Exchange’s Mothers through a series of early pharma partnerships leveraging its CRISPR-based gene modulation platform. Shares of Modalis Therapeutics...
BioCentury | Aug 22, 2020
Translation in Brief

IPD’s synthetic bio unlocks target combos for cell therapy; plus Merck’s oral STING agonist, Surrozen’s regenerative therapy and more

Synthetic switches aim T cells at cells expressing antigen combos David Baker’s team at University of Washington’s Institute for Protein Design published a study in Science showing its synthetic protein switches can direct T cells...
BioCentury | Jun 13, 2020
Translation in Brief

OSE identifies myeloid checkpoint target; plus a call from NCI for COVID-19 test proposals, Sinopharm vaccine data and more

mAbs against new myeloid checkpoint OSE Immunotherapeutics S.A. (Euronext:OSE) has identified CLEC1A, a carbohydrate-binding protein, as a tumor myeloid checkpoint target, and has generated mAbs that prevent CLEC1A from binding its ligand on tumor cells....
BioCentury | May 29, 2020
Distillery Therapeutics

Blocking platelet activation for acetaminophen-induced liver failure

DISEASE CATEGORY: Hepatic INDICATION: Liver failure Inhibiting signaling by the platelet activating receptor CLEC1B could treat acetaminophen-induced liver failure. mRNA levels of PDPN, the cognate ligand of CLEC1B, were higher in tissue from acetaminophen-injured human...
BioCentury | Jan 31, 2020
Distillery Therapeutics

CLEC14A-positive stem cell transplants for muscle regeneration

DISEASE CATEGORY: Musculoskeletal INDICATION: Musculoskeletal Transplantation with muscle-derived CLEC14A-positive stem cells could regenerate muscle following injury, despite lacking expression of known myogenic regulator PAX7. The myogenic cells were isolated from muscle fiber fragments that underwent...
BioCentury | Jan 30, 2020
Company News

As Spinraza’s sales level off, Biogen presses ahead with aducanumab plans

Although Biogen’s earnings report suggests sales of SMA therapy Spinraza have plateaued, the company signaled its continued optimism that FDA will approve another potential blockbuster, its Alzheimer’s disease treatment aducanumab. Revenues from Spinraza nusinersen dipped...
BioCentury | Dec 3, 2019
Clinical News

Biogen plotting next steps in lupus after latest readout

As Biogen seeks to build its immunology franchise, it became the latest company to post encouraging data in lupus, with BIIB059 meeting the primary endpoints in a Phase II trial to treat both cutaneous lupus...
BioCentury | Jul 24, 2019
Distillery Therapeutics

Simultaneous CLEC5A and TLR2 inhibition for dengue

...DISEASE CATEGORY: Infectious disease INDICATION: Dengue fever; viral hemorrhagic fever Simultaneously blocking CLEC5A and TLR2, both...
...mice, CLEC5A knockout or the anti-TLR2 mAb lowered production of NETs and proinflammatory cytokines, and CLEC5A...
...combining the two led to a 90% survival rate in the mice. TARGET/MARKER/PATHWAY: C-type lectin domain family 5 member A (CLEC5A; MDL1...
BioCentury | Jul 23, 2019
Company News

Biogen prioritizing new areas as it awaits SMA landscape changes

Biogen will increasingly prioritize immunology and ophthalmology to better balance risk and reward within its pipeline, executives said during the company's quarterly call Tuesday. As the biotech reported earnings that generally beat expectations, management played...
BioCentury | Jun 1, 2019
Product Development

ASCO 2019 abstracts show solid tumor race heating up among bispecifics and CAR Ts

While strong progress in CAR T therapies will again feature at this year’s ASCO meeting, bispecific antibodies are having a moment -- making more inroads into solid tumors than CAR Ts and branching out via...
Items per page:
1 - 10 of 124